The global Opioid Use Disorder market size will be USD 2965.2 million in 2024.

Name: Opioid Use Disorder Market Analysis 2026
Brand: Cognitive Market Research
SKU: CMR854267
Rating: 4.8 (12 reviews)
Author: Supriya Yadav

Data Timeline	Historical Data: 2022–2025 \| Base Year: 2025 \| Forecast Period: 2026–2034
Drug Type Segment	Buprenorphine, Naltrexone, Methadone
Age Group Segment	19 to 39, 40 to 59, Aged 60 and over

Route of Administration Segment	Oral, Intravenous
Distribution Channel Segment	Hospital Pharmacy, Retail Pharmacy
Regions & Countries	North America (United States, Canada, Mexico) Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe) Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC) South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America) Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East) Africa (East Africa, West Africa, North Africa, South Africa)

Contents

Opioid Use Disorder Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Loading…

Market Dynamics of Opioid Use Disorder Market Analysis

↑ Growth Drivers

Increased opioid addiction rates Increasing awareness and adoption of addiction treatment Growing focus on increasing awareness in government and non-governmental organizations

↓ Restraints

The stigma associated with opioid addiction in society frequently keeps people from getting treatment, which restricts market expansion Inadequate availability of treatment facilities and healthcare professionals, especially in rural areas

~ Trends

The increasing use of telemedicine platforms to provide remote OUD treatment and counseling Rising prioritize of integrated and holistic care

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Opioid Use Disorder Market Analysis — Presence

Interactive World Map

Click countries to explore

Loading map…

Regional and Country Analysis

North America — United States, Canada, Mexico
Europe — United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe
Asia Pacific — China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC
South America — Brazil, Argentina, Colombia, Peru, Chile, Rest of South America
Middle East — Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East
Africa — East Africa, West Africa, North Africa, South Africa

Region / Country	2021 (A)	2025 (A)	2033 (P)	CAGR

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Market size by (Illustrative, 2025)

Share distribution (2025)

Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.

To learn more about market share and segmentation, request the free sample pages.

Competitive Landscape of the Opioid Use Disorder Market

The market for opioid use disorders (OUDs) is very competitive, with major manufacturers like Pfizer, Mallinckrodt, Alkermes, and Indivior holding a monopoly on well-known medication-assisted therapies (MATs) like naltrexone and buprenorphine. Innovative medicines and digital health solutions are the main focus of emerging firms. As the need for efficient OUD management options grows, competition is fueled by developments in treatment efficacy, regulatory approvals, and access expansion initiatives.

March 2023: The goal of Indivior PLC's acquisition of Opiant Pharmaceuticals, Inc. was to enhance the care of patients suffering from overdose or opioid addiction. With this acquisition, the company's position in the market was expected to increase. (Source:https://www.indivior.com/en/media/press-releases/indivior-completes-acquisition-of-opiant-pharmaceuticals-inc) February 2023: The U.S. FDA has received a new drug application (NDA) for Orexo AB's primary pharmaceutical pipeline candidate, OX124, a nasal rescue drug for opioid overdose. (Source:https://orexo.com/news-room/pressreleases-and-news/2023-02-03-orexo-submits-new-drug-application-to-fda-for-ox124-a-high-dose-rescue-medication-for-opioid-overdose) February 2021: ApexB.io, Magellan Rx Management, and Orexo AB worked together to research the application of Modia. Patients with opioid use disorder can benefit from a digital therapy called Modia. (Source:https://orexo.com/news-room/pressreleases-and-news/2021-02-10-orexo-starts-to-test-modia-on-patients-in-collaboration-with-apexb-io-and-magellan-rx-management) June 2020: Titan Pharmaceuticals, Inc. and Indegene have announced plans to expand their capacity to provide Buprenorphine implants for opioid-addicted patients and launch a multichannel digital marketing initiative in the United States. (Source:https://www.titanpharm.com/news/press-releases/detail/238/titan-pharmaceuticals-and-indegene-enter-into-probuphine-co-promotion-partnership)

Click any bar or cell to request the full company profile

Company	2022 (A)	2023 (A)	2024 (A)	2025 (A)
Indivior PLC	•••	•••	•••	•••
Titan Pharmaceuticals	•••	•••	•••	•••
Inc.	•••	•••	•••	•••
Mallinckrodt Pharmaceuticals	•••	•••	•••	•••
BioDelivery Sciences International Inc.	•••	•••	•••	•••
Hikma Pharmaceuticals PLC	•••	•••	•••	•••
Viatris Inc. (Mylan N.V.)	•••	•••	•••	•••
Alkermes	•••	•••	•••	•••
Orexo AB	•••	•••	•••	•••
Camurus	•••	•••	•••	•••

Revenue data requires full access. *2nd & 3rd tier companies available on enquiry.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, the global Opioid Use Disorder market size was USD 2965.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 11.00% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1186.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 889.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.5% from 2024 to 2031.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 682.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 148.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 59.30 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.7% from 2024 to 2031.
The buprenorphine category held the highest Opioid Use Disorder market revenue share in 2024.

Introduction of the Opioid Use Disorder Market

The development, manufacturing, and distribution of therapies and treatments intended to aid in the management and recovery from opioid addiction are all included in the market for opioid use disorder (OUD). Opioid use disorder (OUD) is a recurrent, chronic illness marked by obsessive opioid usage despite negative outcomes. Medication-assisted therapies (MAT) like buprenorphine, naltrexone, and methadone are available in the market, along with counseling and behavioral therapies. Rising rates of opioid addiction, improved access to treatment and awareness, regulatory backing, and improvements in therapy modalities are what are driving market dynamics. Market expansion and development are, nevertheless, also impacted by issues including stigma, societal hurdles, expensive treatment, and uneven access to care.

July 2023: Fedson, Inc. and Titan Pharmaceuticals, Inc. signed an asset purchase agreement. Titan consented to sell certain of its ProNeura assets as part of this agreement, including its portfolio of drugs for addiction treatment and other early-stage ventures built around the ProNeura drug delivery technology. Probuphine and nalmefene implant programs were included in this portfolio. (Source:https://www.titanpharm.com/news/press-releases/detail/268/titan-pharmaceuticals-announces-sale-of-certain-proneura)

Opioid Use Disorder Market Analysis Insights Video

Analyst Conclusion

Conclusion

The global Opioid Use Disorder market will expand significantly by 11.00% CAGR between 2024 and 2031.
Buprenorphine is a medication-assisted treatment (MAT) alternative that is commonly used in the market for treating opioid use disorder (OUD). It helps patients achieve long-term recovery by lowering withdrawal symptoms and cravings.
The intravenous (IV) technique is mostly utilized for the quick, hospital-based administration of medications such as methadone and naloxone, which are essential in detox and emergencies.

Supriya Yadav

Research Analyst · Cognitive Market Research

Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence. Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics. In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments. Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.

LinkedIn Profile Book Appointment

Frequently Asked Questions

What is the market size for the Opioid Use Disorder market in 2024?

The global market size for Opioid Use Disorder in 2024 is USD 2965.2 million.

What is the growth rate for the Opioid Use Disorder market over the forecast period?

The global Opioid Use Disorder market is expected to grow with a CAGR of 11.00% over the projected period.

Which is the leading region of the market for Opioid Use Disorder?

North America held a significant global Opioid Use Disorder market revenue share in 2024.

Which region is projected to detect the fastest growth in the Opioid Use Disorder market over the forecast period?

Asia-Pacific will witness the fastest growth of the global Opioid Use Disorder market over the coming years.

Which country will be leading in the Opioid Use Disorder market in 2024?

The US had the most significant global Opioid Use Disorder market revenue share in 2024.

What are the key drivers for the growth of the Opioid Use Disorder market?

The main drivers of the growth of the Opioid Use Disorder market are the development of new medications and therapies for OUD, expanding treatment options, and governments worldwide implementing policies and funding programs to combat opioid addiction, fueling market growth.

Which is the significant Opioid Use Disorder market segment by drug type?

The buprenorphine category segment had the largest share in the global Opioid Use Disorder market by drug type.

★ Reviews

Rate this report

Opioid Use Disorder Market Analysis — Table of Contents

Disclaimer: Redacted sample for representative purposes. Charts and data do not depict actual statistics. TOC varies by license selection.

Drug Type	Buprenorphine, Naltrexone, Methadone
Age Group	19 to 39, 40 to 59, Aged 60 and over
Route of Administration	Oral, Intravenous
Distribution Channel	Hospital Pharmacy, Retail Pharmacy
List of Competitors	Indivior PLC, Titan Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Hikma Pharmaceuticals PLC, Viatris Inc. (Mylan N.V.), Alkermes, Orexo AB, Camurus

1.1 Global Power Realignment & Strategic Alliances
1.2 Geopolitical Risk Landscape & Conflict Hotspots
1.3 International Trade Relations & Market Access Environment
1.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
1.5 Supply Chain Resilience, Localization & Resource Nationalism
1.6 Technology Sovereignty & Digital Geopolitics
1.7 Strategic Implications for Investment, Growth & Market Entry

2.1 Competitive Landscape Disruption & Strategic Shifts
2.2 AI-Driven Transformation of Industry Value Chain
2.3 Evolution of Business Models & Revenue Streams
2.4 Operational Efficiency & Cost Structure Transformation
2.5 Product, Service & Innovation Acceleration
2.6 Customer Behavior & Demand Evolution
2.7 Future Outlook: AI-Led Market Evolution & Strategic Implications

3.1 Global Opioid Use Disorder Revenue Market Size, Trend Analysis 2022 - 2034
3.2 Global Opioid Use Disorder Volume Market Sales, Trend Analysis 2022 - 2034
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

3.3 Global Opioid Use Disorder Market Size By Regions 2022 - 2034
- 3.3.1 Global Opioid Use Disorder Revenue Market Size By Region
- 3.3.2 Global Opioid Use Disorder Volume Market Sales By Region
3.4 Global Opioid Use Disorder Market Size By Drug Type 2022 - 2034
- 3.4.1 Buprenorphine Market Size
- 3.4.2 Naltrexone Market Size
- 3.4.3 Methadone Market Size
3.5 Global Opioid Use Disorder Volume Market Sales By Drug Type 2022 - 2034
- 3.5.1 Buprenorphine Sales Volume
- 3.5.2 Naltrexone Sales Volume
- 3.5.3 Methadone Sales Volume
3.6 Global Opioid Use Disorder Market Size By Age Group 2022 - 2034
- 3.6.1 19 to 39 Market Size
- 3.6.2 40 to 59 Market Size
- 3.6.3 Aged 60 and over Market Size
3.7 Global Opioid Use Disorder Volume Market Sales By Age Group 2022 - 2034
- 3.7.1 19 to 39 Sales Volume
- 3.7.2 40 to 59 Sales Volume
- 3.7.3 Aged 60 and over Sales Volume
3.8 Global Opioid Use Disorder Market Size By Route of Administration 2022 - 2034
- 3.8.1 Oral Market Size
- 3.8.2 Intravenous Market Size
3.9 Global Opioid Use Disorder Volume Market Sales By Route of Administration 2022 - 2034
- 3.9.1 Oral Sales Volume
- 3.9.2 Intravenous Sales Volume
3.10 Global Opioid Use Disorder Market Size By Distribution Channel for 2022 - 2034
- 3.10.1 Hospital Pharmacy Market Size
- 3.10.2 Retail Pharmacy Market Size
3.11 Global Opioid Use Disorder Volume Market Sales By Distribution Channel 2022 - 2034
- 3.11.1 Hospital Pharmacy Sales Volume
- 3.11.2 Retail Pharmacy Sales Volume
3.12 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)

3.13 Executive Summary Global Market (2021 vs 2025 vs 2033)
- 3.13.1 Regional Market Revenue Summary 2021 vs 2025 vs 2033
- 3.13.2 Regional Volume Market Summary 2021 vs 2025 vs 2033
- 3.13.3 Global Market Revenue Split By Drug Type
- 3.13.4 Global Volume Market Split By Drug Type
- 3.13.5 Global Market Revenue Split By Age Group
- 3.13.6 Global Volume Market Split By Age Group
- 3.13.7 Global Market Revenue Split By Route of Administration
- 3.13.8 Global Volume Market Split By Route of Administration
- 3.13.9 Global Market Revenue Split By Distribution Channel
- 3.13.10 Global Volume Market Split By Distribution Channel
- Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
  
  3.13.11 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities

4.1 North America Opioid Use Disorder Market Outlook
- 4.1.1 North America Opioid Use Disorder Market Size 2022 - 2034
- 4.1.2 North America Opioid Use Disorder Volume Market Sales 2022 - 2034
- 4.1.3 North America Opioid Use Disorder Market Size By Country 2022 - 2034
- 4.1.4 North America Opioid Use Disorder Volume Market Sales By Country 2022 - 2034
- 4.1.5 North America Opioid Use Disorder Market Size by Drug Type 2022 - 2034
  - 4.1.5.1 North America Buprenorphine Market Size
  - 4.1.5.2 North America Naltrexone Market Size
  - 4.1.5.3 North America Methadone Market Size
- 4.1.6 North America Opioid Use Disorder Volume Market Sales by Drug Type 2022 - 2034
  - 4.1.6.1 North America Buprenorphine Sales Volume
  - 4.1.6.2 North America Naltrexone Sales Volume
  - 4.1.6.3 North America Methadone Sales Volume
- 4.1.7 North America Opioid Use Disorder Market Size by Age Group 2022 - 2034
  - 4.1.7.1 North America 19 to 39 Market Size
  - 4.1.7.2 North America 40 to 59 Market Size
  - 4.1.7.3 North America Aged 60 and over Market Size
- 4.1.8 North America Opioid Use Disorder Volume Market Sales by Age Group 2022 - 2034
  - 4.1.8.1 North America 19 to 39 Sales Volume
  - 4.1.8.2 North America 40 to 59 Sales Volume
  - 4.1.8.3 North America Aged 60 and over Sales Volume
- 4.1.9 North America Opioid Use Disorder Market Size by Route of Administration 2022 - 2034
  - 4.1.9.1 North America Oral Market Size
  - 4.1.9.2 North America Intravenous Market Size
- 4.1.10 North America Opioid Use Disorder Volume Market Sales by Route of Administration 2022 - 2034
  - 4.1.10.1 North America Oral Sales Volume
  - 4.1.10.2 North America Intravenous Sales Volume
- 4.1.11 North America Opioid Use Disorder Market Size by Distribution Channel 2022 - 2034
  - 4.1.11.1 North America Hospital Pharmacy Market Size
  - 4.1.11.2 North America Retail Pharmacy Market Size
- 4.1.12 North America Opioid Use Disorder Volume Market Sales by Distribution Channel 2022 - 2034
  - 4.1.12.1 North America Hospital Pharmacy Sales Volume
  - 4.1.12.2 North America Retail Pharmacy Sales Volume

5.1 Europe Opioid Use Disorder Market Outlook
- 5.1.1 Europe Opioid Use Disorder Market Size 2022 - 2034
- 5.1.2 Europe Opioid Use Disorder Volume Market Sales 2022 - 2034
- 5.1.3 Europe Opioid Use Disorder Market Size By Country 2022 - 2034
- 5.1.4 Europe Opioid Use Disorder Volume Market Sales By Country 2022 - 2034
- 5.1.5 Europe Opioid Use Disorder Market Size by Drug Type 2022 - 2034
  - 5.1.5.1 Europe Buprenorphine Market Size
  - 5.1.5.2 Europe Naltrexone Market Size
  - 5.1.5.3 Europe Methadone Market Size
- 5.1.6 Europe Opioid Use Disorder Volume Market Sales by Drug Type 2022 - 2034
  - 5.1.6.1 Europe Buprenorphine Sales Volume
  - 5.1.6.2 Europe Naltrexone Sales Volume
  - 5.1.6.3 Europe Methadone Sales Volume
- 5.1.7 Europe Opioid Use Disorder Market Size by Age Group 2022 - 2034
  - 5.1.7.1 Europe 19 to 39 Market Size
  - 5.1.7.2 Europe 40 to 59 Market Size
  - 5.1.7.3 Europe Aged 60 and over Market Size
- 5.1.8 Europe Opioid Use Disorder Volume Market Sales by Age Group 2022 - 2034
  - 5.1.8.1 Europe 19 to 39 Sales Volume
  - 5.1.8.2 Europe 40 to 59 Sales Volume
  - 5.1.8.3 Europe Aged 60 and over Sales Volume
- 5.1.9 Europe Opioid Use Disorder Market Size by Route of Administration 2022 - 2034
  - 5.1.9.1 Europe Oral Market Size
  - 5.1.9.2 Europe Intravenous Market Size
- 5.1.10 Europe Opioid Use Disorder Volume Market Sales by Route of Administration 2022 - 2034
  - 5.1.10.1 Europe Oral Sales Volume
  - 5.1.10.2 Europe Intravenous Sales Volume
- 5.1.11 Europe Opioid Use Disorder Market Size by Distribution Channel 2022 - 2034
  - 5.1.11.1 Europe Hospital Pharmacy Market Size
  - 5.1.11.2 Europe Retail Pharmacy Market Size
- 5.1.12 Europe Opioid Use Disorder Volume Market Sales by Distribution Channel 2022 - 2034
  - 5.1.12.1 Europe Hospital Pharmacy Sales Volume
  - 5.1.12.2 Europe Retail Pharmacy Sales Volume

6.1 Asia Pacific Opioid Use Disorder Market Outlook
- 6.1.1 Asia Pacific Opioid Use Disorder Market Size 2022 - 2034
- 6.1.2 Asia Pacific Opioid Use Disorder Volume Market Sales 2022 - 2034
- 6.1.3 Asia Pacific Opioid Use Disorder Market Size By Country 2022 - 2034
- 6.1.4 Asia Pacific Opioid Use Disorder Volume Market Sales By Country 2022 - 2034
- 6.1.5 Asia Pacific Opioid Use Disorder Market Size by Drug Type 2022 - 2034
  - 6.1.5.1 Asia Pacific Buprenorphine Market Size
  - 6.1.5.2 Asia Pacific Naltrexone Market Size
  - 6.1.5.3 Asia Pacific Methadone Market Size
- 6.1.6 Asia Pacific Opioid Use Disorder Volume Market Sales by Drug Type 2022 - 2034
  - 6.1.6.1 Asia Pacific Buprenorphine Sales Volume
  - 6.1.6.2 Asia Pacific Naltrexone Sales Volume
  - 6.1.6.3 Asia Pacific Methadone Sales Volume
- 6.1.7 Asia Pacific Opioid Use Disorder Market Size by Age Group 2022 - 2034
  - 6.1.7.1 Asia Pacific 19 to 39 Market Size
  - 6.1.7.2 Asia Pacific 40 to 59 Market Size
  - 6.1.7.3 Asia Pacific Aged 60 and over Market Size
- 6.1.8 Asia Pacific Opioid Use Disorder Volume Market Sales by Age Group 2022 - 2034
  - 6.1.8.1 Asia Pacific 19 to 39 Sales Volume
  - 6.1.8.2 Asia Pacific 40 to 59 Sales Volume
  - 6.1.8.3 Asia Pacific Aged 60 and over Sales Volume
- 6.1.9 Asia Pacific Opioid Use Disorder Market Size by Route of Administration 2022 - 2034
  - 6.1.9.1 Asia Pacific Oral Market Size
  - 6.1.9.2 Asia Pacific Intravenous Market Size
- 6.1.10 Asia Pacific Opioid Use Disorder Volume Market Sales by Route of Administration 2022 - 2034
  - 6.1.10.1 Asia Pacific Oral Sales Volume
  - 6.1.10.2 Asia Pacific Intravenous Sales Volume
- 6.1.11 Asia Pacific Opioid Use Disorder Market Size by Distribution Channel 2022 - 2034
  - 6.1.11.1 Asia Pacific Hospital Pharmacy Market Size
  - 6.1.11.2 Asia Pacific Retail Pharmacy Market Size
- 6.1.12 Asia Pacific Opioid Use Disorder Volume Market Sales by Distribution Channel 2022 - 2034
  - 6.1.12.1 Asia Pacific Hospital Pharmacy Sales Volume
  - 6.1.12.2 Asia Pacific Retail Pharmacy Sales Volume

7.1 South America Opioid Use Disorder Market Outlook
- 7.1.1 South America Opioid Use Disorder Market Size 2022 - 2034
- 7.1.2 South America Opioid Use Disorder Volume Market Sales 2022 - 2034
- 7.1.3 South America Opioid Use Disorder Market Size By Country 2022 - 2034
- 7.1.4 South America Opioid Use Disorder Volume Market Sales By Country 2022 - 2034
- 7.1.5 South America Opioid Use Disorder Market Size by Drug Type 2022 - 2034
  - 7.1.5.1 South America Buprenorphine Market Size
  - 7.1.5.2 South America Naltrexone Market Size
  - 7.1.5.3 South America Methadone Market Size
- 7.1.6 South America Opioid Use Disorder Volume Market Sales by Drug Type 2022 - 2034
  - 7.1.6.1 South America Buprenorphine Sales Volume
  - 7.1.6.2 South America Naltrexone Sales Volume
  - 7.1.6.3 South America Methadone Sales Volume
- 7.1.7 South America Opioid Use Disorder Market Size by Age Group 2022 - 2034
  - 7.1.7.1 South America 19 to 39 Market Size
  - 7.1.7.2 South America 40 to 59 Market Size
  - 7.1.7.3 South America Aged 60 and over Market Size
- 7.1.8 South America Opioid Use Disorder Volume Market Sales by Age Group 2022 - 2034
  - 7.1.8.1 South America 19 to 39 Sales Volume
  - 7.1.8.2 South America 40 to 59 Sales Volume
  - 7.1.8.3 South America Aged 60 and over Sales Volume
- 7.1.9 South America Opioid Use Disorder Market Size by Route of Administration 2022 - 2034
  - 7.1.9.1 South America Oral Market Size
  - 7.1.9.2 South America Intravenous Market Size
- 7.1.10 South America Opioid Use Disorder Volume Market Sales by Route of Administration 2022 - 2034
  - 7.1.10.1 South America Oral Sales Volume
  - 7.1.10.2 South America Intravenous Sales Volume
- 7.1.11 South America Opioid Use Disorder Market Size by Distribution Channel 2022 - 2034
  - 7.1.11.1 South America Hospital Pharmacy Market Size
  - 7.1.11.2 South America Retail Pharmacy Market Size
- 7.1.12 South America Opioid Use Disorder Volume Market Sales by Distribution Channel 2022 - 2034
  - 7.1.12.1 South America Hospital Pharmacy Sales Volume
  - 7.1.12.2 South America Retail Pharmacy Sales Volume

8.1 Middle East Opioid Use Disorder Market Outlook
- 8.1.1 Middle East Opioid Use Disorder Market Size 2022 - 2034
- 8.1.2 Middle East Opioid Use Disorder Volume Market Sales 2022 - 2034
- 8.1.3 Middle East Opioid Use Disorder Market Size By Country 2022 - 2034
- 8.1.4 Middle East Opioid Use Disorder Volume Market Sales By Country 2022 - 2034
- 8.1.5 Middle East Opioid Use Disorder Market Size by Drug Type 2022 - 2034
  - 8.1.5.1 Middle East Buprenorphine Market Size
  - 8.1.5.2 Middle East Naltrexone Market Size
  - 8.1.5.3 Middle East Methadone Market Size
- 8.1.6 Middle East Opioid Use Disorder Volume Market Sales by Drug Type 2022 - 2034
  - 8.1.6.1 Middle East Buprenorphine Sales Volume
  - 8.1.6.2 Middle East Naltrexone Sales Volume
  - 8.1.6.3 Middle East Methadone Sales Volume
- 8.1.7 Middle East Opioid Use Disorder Market Size by Age Group 2022 - 2034
  - 8.1.7.1 Middle East 19 to 39 Market Size
  - 8.1.7.2 Middle East 40 to 59 Market Size
  - 8.1.7.3 Middle East Aged 60 and over Market Size
- 8.1.8 Middle East Opioid Use Disorder Volume Market Sales by Age Group 2022 - 2034
  - 8.1.8.1 Middle East 19 to 39 Sales Volume
  - 8.1.8.2 Middle East 40 to 59 Sales Volume
  - 8.1.8.3 Middle East Aged 60 and over Sales Volume
- 8.1.9 Middle East Opioid Use Disorder Market Size by Route of Administration 2022 - 2034
  - 8.1.9.1 Middle East Oral Market Size
  - 8.1.9.2 Middle East Intravenous Market Size
- 8.1.10 Middle East Opioid Use Disorder Volume Market Sales by Route of Administration 2022 - 2034
  - 8.1.10.1 Middle East Oral Sales Volume
  - 8.1.10.2 Middle East Intravenous Sales Volume
- 8.1.11 Middle East Opioid Use Disorder Market Size by Distribution Channel 2022 - 2034
  - 8.1.11.1 Middle East Hospital Pharmacy Market Size
  - 8.1.11.2 Middle East Retail Pharmacy Market Size
- 8.1.12 Middle East Opioid Use Disorder Volume Market Sales by Distribution Channel 2022 - 2034
  - 8.1.12.1 Middle East Hospital Pharmacy Sales Volume
  - 8.1.12.2 Middle East Retail Pharmacy Sales Volume

9.1 Africa Opioid Use Disorder Market Outlook
- 9.1.1 Africa Opioid Use Disorder Market Size 2022 - 2034
- 9.1.2 Africa Opioid Use Disorder Volume Market Sales 2022 - 2034
- 9.1.3 Africa Opioid Use Disorder Market Size By Country 2022 - 2034
- 9.1.4 Africa Opioid Use Disorder Volume Market Sales By Country 2022 - 2034
- 9.1.5 Africa Opioid Use Disorder Market Size by Drug Type 2022 - 2034
  - 9.1.5.1 Africa Buprenorphine Market Size
  - 9.1.5.2 Africa Naltrexone Market Size
  - 9.1.5.3 Africa Methadone Market Size
- 9.1.6 Africa Opioid Use Disorder Volume Market Sales by Drug Type 2022 - 2034
  - 9.1.6.1 Africa Buprenorphine Sales Volume
  - 9.1.6.2 Africa Naltrexone Sales Volume
  - 9.1.6.3 Africa Methadone Sales Volume
- 9.1.7 Africa Opioid Use Disorder Market Size by Age Group 2022 - 2034
  - 9.1.7.1 Africa 19 to 39 Market Size
  - 9.1.7.2 Africa 40 to 59 Market Size
  - 9.1.7.3 Africa Aged 60 and over Market Size
- 9.1.8 Africa Opioid Use Disorder Volume Market Sales by Age Group 2022 - 2034
  - 9.1.8.1 Africa 19 to 39 Sales Volume
  - 9.1.8.2 Africa 40 to 59 Sales Volume
  - 9.1.8.3 Africa Aged 60 and over Sales Volume
- 9.1.9 Africa Opioid Use Disorder Market Size by Route of Administration 2022 - 2034
  - 9.1.9.1 Africa Oral Market Size
  - 9.1.9.2 Africa Intravenous Market Size
- 9.1.10 Africa Opioid Use Disorder Volume Market Sales by Route of Administration 2022 - 2034
  - 9.1.10.1 Africa Oral Sales Volume
  - 9.1.10.2 Africa Intravenous Sales Volume
- 9.1.11 Africa Opioid Use Disorder Market Size by Distribution Channel 2022 - 2034
  - 9.1.11.1 Africa Hospital Pharmacy Market Size
  - 9.1.11.2 Africa Retail Pharmacy Market Size
- 9.1.12 Africa Opioid Use Disorder Volume Market Sales by Distribution Channel 2022 - 2034
  - 9.1.12.1 Africa Hospital Pharmacy Sales Volume
  - 9.1.12.2 Africa Retail Pharmacy Sales Volume

10.1 Top Competitors Analysis
- (Subject to Data Availability (Private Players))
  
  10.1.1 Global Opioid Use Disorder Market Revenue and Share by Key Players
- 10.1.2 Global Opioid Use Disorder Market Volume and Share by Key Players
- 10.1.3 Top Players Ranking 2024
- 10.1.4 New Product Launch Analysis
- 10.1.5 Industry Mergers and Acquisition Analysis
10.2 Company Profile (Data Subject to Availability) Sample Format
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.1 Indivior PLC
  - 10.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.1.2 Business Overview
  - 10.2.1.3 Financials (Subject to data availability)
  - 10.2.1.4 R&D Investment (Subject to data availability)
  - 10.2.1.5 Product Types Specification
  - 10.2.1.6 Business Strategy
  - 10.2.1.7 Recent Developments
  - 10.2.1.8 Management Change
  - 10.2.1.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.2 Titan Pharmaceuticals
  - 10.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.2.2 Business Overview
  - 10.2.2.3 Financials (Subject to data availability)
  - 10.2.2.4 R&D Investment (Subject to data availability)
  - 10.2.2.5 Product Types Specification
  - 10.2.2.6 Business Strategy
  - 10.2.2.7 Recent Developments
  - 10.2.2.8 Management Change
  - 10.2.2.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.3 Inc.
  - 10.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.3.2 Business Overview
  - 10.2.3.3 Financials (Subject to data availability)
  - 10.2.3.4 R&D Investment (Subject to data availability)
  - 10.2.3.5 Product Types Specification
  - 10.2.3.6 Business Strategy
  - 10.2.3.7 Recent Developments
  - 10.2.3.8 Management Change
  - 10.2.3.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.4 Mallinckrodt Pharmaceuticals
  - 10.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.4.2 Business Overview
  - 10.2.4.3 Financials (Subject to data availability)
  - 10.2.4.4 R&D Investment (Subject to data availability)
  - 10.2.4.5 Product Types Specification
  - 10.2.4.6 Business Strategy
  - 10.2.4.7 Recent Developments
  - 10.2.4.8 Management Change
  - 10.2.4.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.5 BioDelivery Sciences International Inc.
  - 10.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.5.2 Business Overview
  - 10.2.5.3 Financials (Subject to data availability)
  - 10.2.5.4 R&D Investment (Subject to data availability)
  - 10.2.5.5 Product Types Specification
  - 10.2.5.6 Business Strategy
  - 10.2.5.7 Recent Developments
  - 10.2.5.8 Management Change
  - 10.2.5.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.6 Hikma Pharmaceuticals PLC
  - 10.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.6.2 Business Overview
  - 10.2.6.3 Financials (Subject to data availability)
  - 10.2.6.4 R&D Investment (Subject to data availability)
  - 10.2.6.5 Product Types Specification
  - 10.2.6.6 Business Strategy
  - 10.2.6.7 Recent Developments
  - 10.2.6.8 Management Change
  - 10.2.6.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.7 Viatris Inc. (Mylan N.V.)
  - 10.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.7.2 Business Overview
  - 10.2.7.3 Financials (Subject to data availability)
  - 10.2.7.4 R&D Investment (Subject to data availability)
  - 10.2.7.5 Product Types Specification
  - 10.2.7.6 Business Strategy
  - 10.2.7.7 Recent Developments
  - 10.2.7.8 Management Change
  - 10.2.7.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.8 Alkermes
  - 10.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.8.2 Business Overview
  - 10.2.8.3 Financials (Subject to data availability)
  - 10.2.8.4 R&D Investment (Subject to data availability)
  - 10.2.8.5 Product Types Specification
  - 10.2.8.6 Business Strategy
  - 10.2.8.7 Recent Developments
  - 10.2.8.8 Management Change
  - 10.2.8.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.9 Orexo AB
  - 10.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.9.2 Business Overview
  - 10.2.9.3 Financials (Subject to data availability)
  - 10.2.9.4 R&D Investment (Subject to data availability)
  - 10.2.9.5 Product Types Specification
  - 10.2.9.6 Business Strategy
  - 10.2.9.7 Recent Developments
  - 10.2.9.8 Management Change
  - 10.2.9.9 S.W.O.T Analysis
- Data Subject to Availability as we consider Top competitors and their market share will be delivered.
  
  10.2.10 Camurus
  - 10.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
  - 10.2.10.2 Business Overview
  - 10.2.10.3 Financials (Subject to data availability)
  - 10.2.10.4 R&D Investment (Subject to data availability)
  - 10.2.10.5 Product Types Specification
  - 10.2.10.6 Business Strategy
  - 10.2.10.7 Recent Developments
  - 10.2.10.8 Management Change
  - 10.2.10.9 S.W.O.T Analysis

11.1 Market Drivers
11.2 Market Restraints
11.3 Market Trends
11.4 Market Opportunity
11.5 Technological Road Map (Subject to Data Availability)
11.6 Product Life Cycle (Subject to Data Availability)
11.7 Customer and Buyer Behavior Analysis
- 11.7.1 Consumer Demographics and Target Audience Assessment
- 11.7.2 Consumer Purchase Behavior and Demand Assessment
- 11.7.3 Consumer Pricing Dynamics and Affordability Assessment
- 11.7.4 Digital Consumer Engagement and Online Adoption Analysis
- 11.7.5 Future Consumption Trends and Demand Evolution Analysis
- 11.7.6 Enterprise Procurement & Purchasing Behavior Analysis
- 11.7.7 Buyer Decision-Making & Purchase Influence Assessment
- 11.7.8 Customer Expectations & Service Experience Evaluation
- 11.7.9 Vendor Selection & Supplier Preference Analysis
- 11.7.10 Customer Retention & Loyalty Strategy Assessment
- 11.7.11 Pricing Sensitivity & Value Perception Analysis
- 11.7.12 Customer Segmentation & Demand Pattern Analysis
- 11.7.13 Relationship Management & Strategic Partnership Trends
11.8 Market Attractiveness Analysis
11.9 PESTEL Analysis
- 11.9.1 Political Factors
- 11.9.2 Economic Factors
- 11.9.3 Social Factors
- 11.9.4 Technological Factors
- 11.9.5 Legal Factors
- 11.9.6 Environmental Factors
11.10 Industrial Chain Analysis (Subject to Data Availability)
- 11.10.1 Industry Chain Analysis
- 11.10.2 Manufacturing Cost Analysis
- 11.10.3 Supply Side Analysis
  - 11.10.3.1 Raw Material Analysis
  - 11.10.3.2 Raw Material Procurement Analysis
  - 11.10.3.3 Raw Material Price Trend Analysis
11.11 Porter’s Five Forces Analysis
- 11.11.1 Bargaining Power of Suppliers
- 11.11.2 Bargaining Power of Buyers
- 11.11.3 Threat of New Entrants
- 11.11.4 Threat of Substitutes
- 11.11.5 Degree of Competition
11.12 Patent Analysis (Subject to Data Availability)
11.13 ESG Analysis

12.1 Buprenorphine
- 12.1.1 Global Opioid Use Disorder Revenue Market Size and Share by Buprenorphine 2022 - 2034
- 12.1.2 Global Opioid Use Disorder Volume Market Sales by Buprenorphine 2022 - 2034
12.2 Naltrexone
- 12.2.1 Global Opioid Use Disorder Revenue Market Size and Share by Naltrexone 2022 - 2034
- 12.2.2 Global Opioid Use Disorder Volume Market Sales by Naltrexone 2022 - 2034
12.3 Methadone
- 12.3.1 Global Opioid Use Disorder Revenue Market Size and Share by Methadone 2022 - 2034
- 12.3.2 Global Opioid Use Disorder Volume Market Sales by Methadone 2022 - 2034

13.1 19 to 39
- 13.1.1 Global Opioid Use Disorder Revenue Market Size and Share by 19 to 39 2022 - 2034
- 13.1.2 Global Opioid Use Disorder Volume Market Sales by 19 to 39 2022 - 2034
13.2 40 to 59
- 13.2.1 Global Opioid Use Disorder Revenue Market Size and Share by 40 to 59 2022 - 2034
- 13.2.2 Global Opioid Use Disorder Volume Market Sales by 40 to 59 2022 - 2034
13.3 Aged 60 and over
- 13.3.1 Global Opioid Use Disorder Revenue Market Size and Share by Aged 60 and over 2022 - 2034
- 13.3.2 Global Opioid Use Disorder Volume Market Sales by Aged 60 and over 2022 - 2034

14.1 Oral
- 14.1.1 Global Opioid Use Disorder Revenue Market Size and Share by Oral 2022 - 2034
- 14.1.2 Global Opioid Use Disorder Volume Market Sales by Oral 2022 - 2034
14.2 Intravenous
- 14.2.1 Global Opioid Use Disorder Revenue Market Size and Share by Intravenous 2022 - 2034
- 14.2.2 Global Opioid Use Disorder Volume Market Sales by Intravenous 2022 - 2034

15.1 Hospital Pharmacy
- 15.1.1 Global Opioid Use Disorder Revenue Market Size and Share by Hospital Pharmacy 2022 - 2034
- 15.1.2 Global Opioid Use Disorder Volume Market Sales by Hospital Pharmacy 2022 - 2034
15.2 Retail Pharmacy
- 15.2.1 Global Opioid Use Disorder Revenue Market Size and Share by Retail Pharmacy 2022 - 2034
- 15.2.2 Global Opioid Use Disorder Volume Market Sales by Retail Pharmacy 2022 - 2034

16.1 Company Gap Assessment Analysis
16.2 Product & Service Portfolio Gap Analysis
16.3 Demand-Supply Imbalance Analysis
16.4 Market Opportunity & Unmet Needs Analysis
16.5 Technology Adoption & Digital Transformation Gap Analysis
16.6 Operational Efficiency & Process Gap Analysis
16.7 Infrastructure & Capacity Gap Analysis
16.8 Geographic Coverage & Distribution Gap Analysis
16.9 Investment Opportunity & Funding Gap Analysis
16.10 Pricing Structure & Margin Gap Analysis
16.11 Innovation & R&D Capability Gap Analysis
16.12 Policy, Compliance & Regulatory Gap Analysis
16.13 Customer Experience & Expectation Gap Analysis
16.14 Future Growth Opportunity Gap Analysis
16.15 Market Accessibility & Penetration Gap Analysis

17.1 Gross Margin Overview and Industry Profitability Trends
17.2 Regional Gross Margin Performance Analysis
17.3 Supply Chain and Distribution Impact on Gross Margins
17.4 Pricing Strategy and Value-Added Margin Assessment
17.5 Key Factors Influencing Gross Margin Variability
17.6 Future Gross Margin Outlook and Profitability Trends

18.1 Key Takeaways
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.

18.2 Analyst Point of View
18.3 Assumptions and Acronyms

19.1 Primary Data Collection
- 19.1.1 Steps for Primary Data Collection
  - 19.1.1.1 Identification of KOL
- 19.1.2 Backward Integration
- 19.1.3 Forward Integration
- 19.1.4 How Primary Research Help Us
- 19.1.5 Modes of Primary Research
19.2 Secondary Research
- 19.2.1 How Secondary Research Help Us
- 19.2.2 Sources of Secondary Research
19.3 Data Validation
- 19.3.1 Data Triangulation
- 19.3.2 Top Down & Bottom Up Approach
- 19.3.3 Cross check KOL Responses with Secondary Data
19.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research employs "The Full Truth™" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Opioid Use Disorder Market Analysis Market analysis.

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics

Data Points Validated 10,400+

Expert Interviews 54

Countries Covered 39+

Company Profiles 10+

Forecast Accuracy (Historical) 94.2%

Report Pages 250+

Analytical Coverage

Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest News about Opioid Use Disorder Market

Sources from Pharma & Healthcare Industry

How We Serve You

Three Pillars of Market Intelligence

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Opioid Use Disorder Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the opioid use disorder market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included

Buyer intent & sentiment analysis
Purchase cycle mapping
Price sensitivity research
Channel preference profiling
Competitive perception study

Most Requested

Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included

Ready syndicate report (250+ pages)
Custom data scope & segmentation
Excel quantitative models
Board-ready PPT with key findings
Secure cloud portal access

Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included